AstraZeneca PLC (AZN)
NASDAQ: AZN · IEX Real-Time Price · USD
76.99
-0.95 (-1.22%)
At close: Jul 2, 2024, 4:00 PM
77.10
+0.11 (0.14%)
After-hours: Jul 2, 2024, 7:59 PM EDT
AstraZeneca Employees
AstraZeneca had 89,900 employees as of December 31, 2023. The number of employees increased by 6,400 or 7.66% compared to the previous year.
Employees
89,900
Change (1Y)
6,400
Growth (1Y)
7.66%
Revenue / Employee
$529,600
Profits / Employee
$70,423
Market Cap
238.71B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
Dec 31, 2022 | 83,500 | 400 | 0.48% |
Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
Dec 31, 2013 | 51,500 | -200 | -0.39% |
Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
Dec 31, 2007 | 67,400 | 600 | 0.90% |
Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
AZN News
- 1 day ago - AstraZeneca's COVID prevention drug application gets EU fast-track assessment - Reuters
- 5 days ago - German vaccine panel endorses Astra-Sanofi's RSV shot for infants - Reuters
- 6 days ago - Tanium Plays Critical Role in Supporting AstraZeneca's Mission to Deliver Life-Changing Medicines - Business Wire
- 6 days ago - China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment - Reuters
- 7 days ago - AstraZeneca says Imfinzi fails in late-stage trial to treat type of lung cancer - Reuters
- 14 days ago - AstraZeneca's breast cancer drug combination fails in late-stage trial - Reuters
- 15 days ago - AstraZeneca's lung cancer drug approved by US FDA for combination chemotherapy treatment - Invezz
- 15 days ago - IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer - Business Wire